| Revenue growth | FY26 India growth 9%; International formulations FY26 growth 2%. |
|---|---|
| Margins | Gross margin improved to 70% from 66% due to product mix. |
| Order book | Sufficient number of new CDMO projects/contracts on hand. |
| Demand visibility | Strong brand equity in chronic/cardiac segments providing visibility. |
| Management confidence | High confidence in branded portfolio acceleration post-integration. |
Growth
Revenue fell 5% to ₹904cr. Branded India business grew 8% in Q4; FY26 India business grew 9% to ₹2,461cr.
Outlook
Expects gradual recovery to double-digit growth in India and single-digit in International; merger with Torrent nearing completion.
Risks
Container constraints in West Asia and Southeast Asia; integration-related temporary slowdown in India and international volumes.
Earnings Call filed with NSE, NSE: JBCHEPHARM. Summary written with AI assistance from the document.
More from J B Chemicals & Pharmaceuticals Ltd
All →Jb Chemicals & Pharmaceuticals Merger & Restructuring
JB Chemicals & Pharmaceuticals' amalgamation with Torrent Pharmaceuticals received NCLT sanction. The scheme will become effective upon filing with the Registrar of Companies.
Jb Chemicals & Pharmaceuticals Management Change
Pradeep Kumar Singh and Suresh Bhise retired from the company. These changes in senior management are effective from June 30, 2026.
Jb Chemicals & Pharmaceuticals Price Movement Clarification
JB Chemicals clarified its audited financial results to the exchange. The board-approved results were signed by a director as authorized.
Jb Chemicals & Pharmaceuticals Management Change
Mr. Bhushan Sachdev resigned as Executive Vice President – Supply Chain Management effective June 12, 2026. Investors should note the departure of a key supply chain executive.
Jb Chemicals & Pharmaceuticals Annual Report
JB Chemicals & Pharmaceuticals Limited filed its Business Responsibility and Sustainability Report for FY 2025-26. The report details company ESG performance, sustainability targets, and governance frameworks.
Jb Chemicals & Pharmaceuticals Annual Report
JB Chemicals & Pharmaceuticals filed its FY26 Business Responsibility and Sustainability Report. The filing highlights its ₹3889.89 Crore turnover and ESG progress for investor review.
- Value
- ₹3,890 Cr